Todos os estudos
Inscrição por conviteOBSERVACIONAL

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®

This study is gathering information about a medicine called Esperoct® (turoctocog alfa pegol (N8-GP)). It's for males of all ages who have haemophilia A and are already taking Esperoct® to prevent bleeds. The aim is to see how well the medicine works over a long time and if there are any side effects. You'll get the same care you normally would, and your doctor will ask about your health and any bleeds since your last visit. You'll also keep a diary of your bleeds. The study will last about 5 to 7 years. You can choose to leave the study at any time, and it won't affect your medical care.

Em resumo

Status
Inscrição por convite
Patrocinador
Novo Nordisk A/S
Meta de inscrição
60
Iniciar
23 Out 2020
Conclusão estimada
03 Jun 2027

Sobre o que é este estudo?

This study is about a medicine called Esperoct® (sometimes known as turoctocog alfa pegol or N8-GP). It's specifically for males who have haemophilia A. Haemophilia A is a condition where your blood doesn't clot properly, leading to easier bleeding. Esperoct® is a treatment given regularly to help prevent these bleeds.

The main goal of this study is to collect information over a long time – around 5 to 7 years – about how well Esperoct® works in preventing bleeds and whether it causes any side effects. Doctors want to understand its long-term effects in people using it as part of their regular treatment to prevent bleeds.

It's important to know that taking part in this study means you'll continue to get the same medical care and treatment as you usually would. The study is simply looking at how Esperoct® is used in real life. Your participation helps doctors learn more about this medicine to help others with haemophilia A in the future.

Pontos principais

  • This study is for males with haemophilia A who use Esperoct®.
  • It aims to understand Esperoct®'s long-term effectiveness and side effects.
  • Your treatment and medical care won't change if you join.
  • You'll share information about your bleeds and health over 5-7 years.
  • Participation is voluntary, and you can leave at any time without affecting your care.
  • Your involvement helps improve understanding of haemophilia A treatment.

Quem pode ser elegível?

This study is for males of any age who have been diagnosed with moderate or severe haemophilia A. You must already be using or be about to start using the regular preventive treatment, Esperoct®. The decision for you to use Esperoct® must have been made by you and your doctor independently, before you decide to join this study.

Before you can take part, you'll need to read and sign a consent form, showing you understand what's involved. This is a very important step to make sure you're comfortable with everything.

You cannot join the study if you've been in it before, or if you're allergic to Esperoct® or similar medicines. Also, if your doctor suspects you have 'inhibitors' (antibodies that stop the medicine from working) or if you have difficulty understanding the study information, you won't be able to participate.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você é do sexo masculino?
  2. Do you have moderate or severe haemophilia A?
  3. Are you currently using or about to start using Esperoct® for regular prevention?
  4. Has the decision to use Esperoct® already been made by you and your doctor?
  5. Are you comfortable signing a consent form to participate?
  6. Do you understand the study information and feel able to cooperate?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to join this study, it means you'll continue with your usual medical appointments and treatment with Esperoct® as prescribed by your doctor. The study doesn't change your treatment plan. Your clinic visits will be just like your normal check-ups.

During these visits, the study doctor might ask you some questions about your health and if you've had any side effects since your last visit. They might also suggest some routine tests if they think it's helpful. You'll be asked to keep a simple diary at home, noting down any bleeds you have, how you treated them, and when you took your regular Esperoct® medicine.

Your participation in this study will last for quite a while, typically between 5 to 7 years, depending on when you start. You have the right to leave the study at any time, for any reason, and this decision will not affect your current or future medical care in any way.

Riscos e benefícios potenciais

Taking part in this study won't change your medical care, so you'll continue to receive the same treatment you usually would. There aren't any extra medical procedures for the study, which means no additional medical risks. The main benefit is knowing you're helping medical experts learn more about how Esperoct® works over time, which can help other people with haemophilia A in the future. You always have the right to leave the study at any point, and your care will not be affected.

Locations (27)

  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
    Código postal verificado
    Viena, Áustria
  • UMHAT "Tsaritsa Yoanna-ISUL"
    Código postal verificado
    Sofia, Bulgaria
  • KBC Zagreb, Rebro, Hemofilija centar
    Código postal verificado
    Zagreb, Croácia
  • FN Brno odd. hematologie
    Código postal verificado
    Brno, Tchéquia
  • FN HK - IV. Interni hematologicka klinika
    Código postal verificado
    Hradec Králové, Czechia
  • North Estonia Medical Centre Foundation
    Código postal verificado
    Tallinn, Estonia
  • Tartu University Hospital Haematology Clinic
    Código postal verificado
    Tartu, Estonia
  • Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
    Código postal verificado
    Berlim, Alemanha
  • Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
    Código postal verificado
    Bonn, Alemanha
  • "Laiko" General Hospital of Athens
    Código postal verificado
    Athens, Greece
  • "Laiko" General Hospital of Athens
    Código postal verificado
    Athens, Greece
  • Aghia Sophia Childrens' Hospital
    Código postal verificado
    Athens, Greece

Perguntas frequentes

What is Esperoct®?

Esperoct® is a medicine used to prevent bleeding in people with haemophilia A.

Do I have to do anything differently with my medicine if I join?

No, you will continue to take Esperoct® exactly as your doctor has prescribed; the study doesn't change your treatment.

Quanto tempo o estudo durará para mim?

The study will last for about 5 to 7 years, depending on when you start.

Can I leave the study whenever I want?

Yes, you are free to leave the study at any time, for any reason, and it won't impact your medical care.

What information will I need to share?

You'll be asked about any bleeds and side effects, and to keep a diary of your bleeds and when you take your medicine.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study Following Males With Haemophilia A on Prophylaxis Wi…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.